The shift from N-of-1 to N-of-many in gene-based personalized therapies is reshaping how pharmaceutical organizations approach development at scale. But scaling CRISPR-based therapies across hundreds of variants is not just a scientific challenge; it introduces new complexities in clinical design, regulatory alignment and quality control.

At ASGCT 2026, panel speakers explore how umbrella trial designs may help streamline clinical development for variant-specific therapies, while also highlighting the challenges introduced by rapidly evolving regulatory frameworks and expectations.

1. How is personalized medicine evolving beyond one-therapy-at-a-time development?

Personalized gene editing is evolving from creating a completely new therapy for each disease to creating a reusable therapeutic platform that can be rapidly adapted across indications. Traditional gene therapy requires separate discovery, preclinical, manufacturing and regulatory pathways for every single mutation.

In contrast, precision gene editing platforms maintain consistent core therapeutic components, such as the lipid nanoparticle (LNP) delivery vehicle and Cas9 enzyme, which remain largely unchanged, while small modifications to the guide RNA (gRNA) and/or the base editor mRNA redirect treatment to different disease-causing genes.

In practice, this allows a CRISPR-based therapy initially developed for one indication, such as cardiovascular disease, to be applied to genetic disorders, such as phenylketonuria (PKU) and urea cycle disorders (UCD). By leveraging a common platform rather than creating entirely new therapies for each condition, drug developers can scale CRISPR-based personalized medicine across hundreds of genetic diseases while streamlining development and regulatory pathways.

2. How are umbrella trials enabling faster development of variant-specific therapies?

As platform-based approaches evolve, clinical trial design is also adapting to support greater efficiency. Umbrella clinical trials, in this case, can accelerate the development of variant-specific gene therapies by evaluating multiple versions of a CRISPR therapeutic under a single clinical and regulatory framework.

For example, six gene editing therapies targeting different PKU variants could be included in a single IND application and clinical trial, since the underlying LNP and editing machinery remain constant. This approach reduces the need for duplicate toxicology studies and streamlines regulatory review, while allowing researchers to compare efficacy and safety profiles of different drug versions more effectively.

More importantly, the FDA also indicated that additional variants could potentially be incorporated into the trial as they are discovered, based primarily on cellular validation data rather than new animal studies. This permission enables continuous expansion of a clinical program in real time, allowing drug sponsors to respond more rapidly to newly identified patient variants while leveraging existing safety, manufacturing and regulatory data.

3. What changes are happening in how regulatory bodies evaluate these therapies?

Regulatory agencies are adapting their evaluation frameworks to accommodate increasingly modular and individualized gene therapies. A key shift is the growing openness to platform-based evaluation, in which multiple variant-specific therapies can share a common preclinical evidence package. At the same time, delivery systems, editing machinery and manufacturing processes remain largely unchanged. Rather than assessing each variant in isolation, regulators are considering shared platform components alongside variant-specific elements.

For clinical development, the FDA supported the use of master protocols to evaluate multiple variants and diseases within a single trial framework, while maintaining gene-level oversight through separate but cross-referenced INDs and biologics license applications (BLAs). This reflects an effort to balance between flexibility and appropriate regulatory control.

Another important shift is the FDA’s draft “plausible mechanism” framework for individualized therapies in rare genetic diseases. Recognizing that large-scale trials may not be feasible in ultra-rare settings, this approach emphasizes mechanistic understanding, platform consistency and smaller patient datasets, while allowing evidence from earlier programs to inform subsequent programs.

At the same time, this flexibility is paired with rigorous CMC and analytical expectations. Developers are expected to establish cGMP-compliant manufacturing processes, validated analytical methods and robust process validation strategies early in development.

We see a way to accelerate breakthroughs that could transform the life for one million people living with rare diseases

Learn More

4. Why are analytics and QC becoming the limiting factor?

As gene therapy manufacturing challenges are increasingly addressed through platform-based and automated production systems, the bottleneck is shifting away from manufacturing itself and toward analytics and quality control (QC).

Even with improved consistency in CRISPR scalability and manufacturing workflows, each individualized or variant-specific therapy still requires rigorous confirmation of identity, purity and safety before release. This includes time-sensitive off-target analysis and batch release testing, which remain difficult to standardize across different guide RNAs or genetic targets. As a result, even when manufacturing is completed efficiently, batches often remain on hold during QC review, making analytics the rate-limiting step in clinical readiness.

This challenge becomes more pronounced as development timelines accelerate. The vision for next-generation gene editing programs is to transition from digital sequence to a clinical-grade product in under a month, placing extreme pressure on analytical turnaround times and validation workflows. However, current QC systems remain fragmented, with limited cross-program data integration and high assay customization.

This fragmentation limits automation and slows the development of reusable validation frameworks across therapeutic variants. Until analytical workflows become more standardized, scalable and integrated, QC will remain a key constraint on realizing the full potential of platform-based gene editing.

Watch the full panel discussion to discover how integrated capabilities across LNP delivery, genome editing and analytics can help streamline development and support regulatory success.